"Recently" Priced IPO's and Secondaries
They are a growing specialty insurance company delivering commercial property and casualty (“P&C”) products and solutions on a non-admitted (or excess and surplus (“E&S”)) and admitted basis, predominantly in the United States.
Barclays, Keefe Bruyette & Woods, Jefferies
William Blair, JMP Securities, Piper Sandler, Raymond James, Truist, TD Cowen, Nomura
Secondary
They are a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases.
Piper Sandler, Guggenheim
Secondary
They have grown into one of the world’s leading travel companies, with a fleet of 92 small, state-of-the-art ships, which they view as floating hotels.
BofA Securities, J.P. Morgan, UBS Investment Bank, Wells Fargo Securities, HSBC, Morgan Stanley
Rothschild & Co., Stifel
IPO
IPO
Piper Sandler, BofA Securities
Secondary
Evercore, Jefferies, Baird, Wells Fargo Securities, Wolfe Nomura Alliance
Roth Capital
Secondary
Leerink
Secondary
Marex is a diversified global financial services platform providing essential liquidity, market access and infrastructure services to clients across energy, commodities and financial markets.
Barclays, Goldman Sachs, Jefferies, Keefe Bruyette & Woods, Citigroup, UBS Investment Bank, Piper Sandler, HSBC, Drexel Hamilton, Loop Capital Markets (Listed Alphabetically)
IPO
IPO
They are on a mission to secure the world’s data.
Goldman Sachs, Barclays, Citigroup, Wells Fargo Securities
Guggenheim Securities, Mizuho , Truist Securities, BMO Capital Markets, Deutsche Bank Securities, KeyBanc Capital, Cantor, CIBC Capital Markets, Capital One Securities, Wedbush Securities, SMBC Nikko
IPO
IPO
They specialize in the design, manufacture, and sale of niche aerospace and defense components that are essential for today’s aircraft and aerospace and defense systems.
Jefferies, Morgan Stanley, Moelis & Company, Citigroup, RBC Capital
IPO
IPO
They are reimagining the traditional pharmaceutical research and development model to build, from the bottom-up, an R&D engine predicated on asset centricity to discover, develop and ultimately deliver impactful medicines to patients.
Goldman Sachs, Leerink Securities, Evercore ISI, Guggenheim Securities, BMO Capital Markets
Secondary